An OrbiMed-backed startup looks to cut excess corticosteroids with mid-stage tests for its lead drug queued up

OrbiMed has had a busy few months with a slate of startups launching out of its always productive pipeline of business concepts. Now, an OrbiMed-backed player in Oregon is looking to tamp down intracellular steroid toxicity, and it’s got a healthy check to get off the ground.